Search Result

Results for "

tumor suppressor protein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (2) Antibiotic (1) Apoptosis (6) Bacterial (1) CDK (1) CRM1 (1) Deubiquitinase (1) E1/E2/E3 Enzyme (2) Endogenous Metabolite (5) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (3) Histone Demethylase (5) Histone Methyltransferase (1) Isotope-Labeled Compounds (2) Ligands for Target Protein for PROTAC (1) Liposome (1) MASTL (1) MDM-2/p53 (6) MMP (1) mRNA (2) Parasite (1) PD-1/PD-L1 (1) PTEN (1) Raf (1) Reference Standards (1) TGF-β Receptor (2) VEGFR (1) Wee1 (4)
By Research Areas:	Cancer (37) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (1) Metabolic Disease (2) Neurological Disease (4)
Oligonucleotides:	mRNA (2) Cationic Lipids (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: HRASLS TNF Receptor BRK VISTA

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117737A

RRD-251	Raf Apoptosis	Cancer
RRD-251 is an inhibitor of *retinoblastoma tumor* suppressor protein (Rb)-Raf-1 interaction*, with potent anti-proliferative, anti-angiogenic and anti-tumor* activities .

HY-161254

ATPase-IN-3	Apoptosis MDM-2/p53	Inflammation/Immunology Cancer
ATPase-IN-3 (compound 6) is a ATPase inhibitor. ATPase-IN-3 has Gastroprotective effect in ethanol-induced gastric ulcers by contribution of anti-apoptotic (BCL-2) and tumor suppressor (P53) proteins .

HY-135199

Ubiquitination-IN-1	E1/E2/E3 Enzyme	Cancer
Ubiquitination-IN-1 (compound 24) is a ubiquitination and Cksl-Skp2 protein-protein interaction (IC₅₀=0.17 μM) inhibitor. Ubiquitination-IN-1 increases levels of p27. Ubiquitination-IN-1 has the potential for treatment disease by blocking the degradation of tumor suppressors .

HY-152859

Brigimadlin BI 907828	E1/E2/E3 Enzyme MDM-2/p53	Cancer
Brigimadlin (BI 907828) is an orally active E3 ubiquitin-protein ligase MDM-2 inhibitor, preventing MDM-2 from negatively regulating the tumor suppressor p53. Brigimadlin can be used for antineoplastic research .

HY-156633

Rezatapopt PC14586	MDM-2/p53	Cancer
Rezatapopt (PC14586) is an orally active antineoplastic agent. Rezatapopt binds to a pocket created by the TP53 Y220C mutation. Rezatapopt restores p53 tumor suppressor functions by stabilization of the p53 protein structure. Rezatapopt demonstrates tumor inhibition and regression in mouse models with established human tumor xenografts harboring the TP53 Y220C mutation .

HY-P10295

p53 (232-240)	MDM-2/p53	Cancer
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .

HY-174511

Human TP53 mRNA	mRNA	Cancer
Human TP53 mRNA encodes the human tumor protein p53 (TP53) protein, a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. TP53 responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism.

HY-16271S

Kevetrin-13C2,15N3 hydrochloride 4-Isothioureidobutyronitrile-¹³C₂,¹⁵N₃ hydrochloride; thioureidobutyronitrile -¹³C₂,¹⁵N₃ hydrochloride	Isotope-Labeled Compounds MDM-2/p53	Cancer
Kevetrin (hydrochloride)- ¹³C₂, ¹⁵N₃ is the ¹³C-labeled and ¹⁵N-labeled Kevetrin (hydrochloride). Kevetrin hydrochloride is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity.

HY-174777

Human BAK1 mRNA	mRNA	Cancer
Human BAK1 mRNA encodes the human BCL2 antagonist/killer 1 (BAK1) protein, a member of the BCL2 protein family. BAK1 localizes to mitochondria, and functions to induce apoptosis. It also interacts with the tumor suppressor P53 after exposure to cell stress.

HY-E70866

TGFβR1 Recombinant Human Active Protein Kinase	TGF-β Receptor	Cancer
TGFβR1 plays an important role in TGF-β signaling transduction and serves as a tumor suppressor. TGFβR1 Recombinant Human Active Protein Kinase is a recombinant TGFβR1 protein that can be used to study TGFβR1-related functions .

HY-P10553

ARF(26–44), cell-permeable	Apoptosis	Cancer
ARF(26–44), cell-permeable is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. As a functional inhibitor of FoxM1, ARF(26–44) cell-permeable shows significant anti-tumor activity in the treatment of mouse hepatocellular carcinoma (HCC), significantly increasing tumor cell apoptosis and reducing tumor cell proliferation and angiogenesis. ARF(26–44), cell-permeable can be used in research on tumor therapy .

HY-B1336

Furazolidone 3 Publications Verification	Bacterial Apoptosis Antibiotic Parasite	Infection Cancer
Furazolidone is a monoamine oxidase (MAO) inhibitor with antiproliferative, apoptosis-inducing and differentiation-promoting activities. Furazolidone may inhibit leukemia fusion protein-mediated bone marrow transformation by upregulating the stability of the tumor suppressor protein p53. Furazolidone exhibits anti-leukemic activity in acute myeloid leukemia (AML) cell lines and can be used for anti-AML research [2].

HY-E70743

MASTL Recombinant Human Active Protein Kinase	MASTL	Cancer
MASTL kinase is a master regulator of mitosis, essential for ensuring that mitotic substrate phosphorylation is correctly maintained. It achieves this through the phosphorylation of alpha-endosulfine and subsequent inhibition of the tumor suppressor PP2A-B55 phosphatase. MASTL Recombinant Human Active Protein Kinase is a recombinant MASTL protein that can be used to study MASTL-related functions .

HY-116896A

LY117018 TFA	Estrogen Receptor/ERR	Cancer
LY117018 TFA, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 TFA exerts antiproliferative effects on breast cancer cell lines .

HY-116896R

LY117018 (Standard)	Estrogen Receptor/ERR	Cancer
LY117018 (Standard) is the analytical standard of LY117018. This product is intended for research and analytical applications. LY117018, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 exerts antiproliferative effects on breast cancer cell lines .

HY-116896

LY117018	Estrogen Receptor/ERR	Cancer
LY117018, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 exerts antiproliferative effects on breast cancer cell lines .

HY-E70851

Nuak2 Recombinant Human Active Protein Kinase	AMPK	Cancer
NUAK2 is a member of the SNF1/AMP kinase (AMPK) family (serine/threonine kinases) that is regulated by the putative tumor suppressor LKB1 (20-23) and also by death receptor signaling through NF-κB. Nuak2 Recombinant Human Active Protein Kinase is a recombinant Nuak2 protein that can be used to study Nuak2-related functions .

HY-146384

CRM1 degrader 1	CRM1	Cancer
CRM1 degrader 1 (1l) is a low toxic chromosome region maintenance 1 (CRM1) degrader. CRM1 is the sole nuclear exporter of several tumor suppressor, a growth regulatory protein as an attractive cancer agent target. CRM1 degrader 1 induces the apoptosis in gastric carcinoma and selectively inhibits proliferation of gastric cancer .

HY-E70802

Biotin-Nuak2 Recombinant Human Active Protein Kinase	AMPK	Cancer
NUAK2 is a member of the SNF1/AMP kinase (AMPK) family (serine/threonine kinases) that is regulated by the putative tumor suppressor LKB1 (20-23) and also by death receptor signaling through NF-κB. Biotin-Nuak2 Recombinant Human Active Protein Kinase is a recombinant Nuak2 protein that can be used to study Nuak2-related functions, and is biotinylated .

HY-146887

USP7-IN-9	Deubiquitinase Apoptosis	Cancer
USP7-IN-9 is a highly potent ubiquitin-specific protease 7 (USP7) inhibitor with an IC₅₀ value of 40.8 nM. USP7-IN-9 can induce apoptosis and arrest cell progression at G0/G1 and S phases in RS4; 11 cells. USP7-IN-9 reduces the protein levels of oncoproteins MDM2 and DNMT1 and increases the protein levels of tumor suppressors p53 and p21 .

HY-151595

Menin-MLL inhibitor-22	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor-22 (compound C20) is an orally active inhibitor of the interaction between menin and mixed lineage leukemia (MLL) (IC₅₀=7 nM). Menin-MLL inhibitor-22 binds menin protein and inhibits cancer cell growth (MV4 cells, IC₅₀=0.3 μM). Menin is a putative tumor suppressor associated with multiple endocrine neoplasia type 1 (MEN-1 syndrome) .

HY-133754

MI-1063	MDM-2/p53 Ligands for Target Protein for PROTAC	Cancer
MI-1063 is an inhibitor for DMD-2, that blocks the MDM2-p53 interaction, and activates the tumor suppressor function of p53. MI-1063 inhibits the growth of cancer cell RS4-11 and MV4-11 with IC₅₀ of 179 nM and 93 nM. MI-1063 can be used as target protein ligand in synthesis of PROTAC degrader MD-265 (HY-169327) .

HY-E70867

TGFβR2 Recombinant Human Active Protein Kinase	TGF-β Receptor	Metabolic Disease
TGF-β is a pleiotropic multifunctional cytokine that regulates many cellular processes, such as cell growth, differentiation, apoptosis and cellular homeostasis. Before exerting the biological effects within cells, TGF-β first requires extracellular activation, namely binds to its type II receptor (TGFβR2) and promotes the phosphorylation. TGFβR1 plays an important role in TGF-β signaling transduction and serves as a tumor suppressor. TGFβR2 Recombinant Human Active Protein Kinase is a recombinant TGFβR2 protein that can be used to study TGFβR2-related functions .

HY-143342

LEB-03-144	Wee1	Cancer
LEB-03-144 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through a C3 alkyl linker. LEB-03-144 shows significant WEE1 stabilization in HEP3B hepatoma cancer cells .

HY-144999

LEB-03-146	Wee1	Cancer
LEB-03-146 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through a PEG2 linker. LEB-03-146 shows significant WEE1 stabilization in HEP3B hepatoma cancer cells .

HY-143340

LEB-03-145	Wee1	Cancer
LEB-03-145 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through a C5 alkyl linker .

HY-143343

LEB-03-153	Wee1	Cancer
LEB-03-153 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through no linker .

HY-W011269

Eicosapentaenoic Acid sodium EPA sodium; Timnodonic acid sodium	Endogenous Metabolite Histone Demethylase	Cardiovascular Disease Metabolic Disease Cancer
Eicosapentaenoic Acid (EPA)sodium is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid sodium exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid sodium activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid sodium can promote relaxation of vascular smooth muscle cells and vasodilation .

HY-B0660

Eicosapentaenoic Acid Maximum Cited Publications 25 Publications Verification EPA; Timnodonic acid	Endogenous Metabolite Histone Demethylase	Neurological Disease Cancer
Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .

HY-B0660A

Eicosapentaenoic acid (metformin) EPA (metformin); Timnodonic acid (metformin)	Endogenous Metabolite Histone Demethylase	Neurological Disease Cancer
Eicosapentaenoic Acid (EPA) metformin is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic acid metformin exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). EEicosapentaenoic acid metformin activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic acid metformin can promote relaxation of vascular smooth muscle cells and vasodilation .

HY-101508

GNA002	Histone Methyltransferase	Cancer
GNA002 is a highly potent, specific and covalent EZH2 (Enhancer of zeste homolog 2) inhibitor with an IC₅₀ of 1.1 μM. GNA002 can specifically and covalently bind to Cys668 within the EZH2-SET domain, triggering EZH2 degradation through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination. GNA002 efficiently reduces EZH2-mediated H3K27 trimethylation, reactivates polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes .

HY-P1109

[Ala92]-p16 (84-103)	CDK	Cancer
[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a (p16) tumor suppressor protein. [Ala92]-p16 (84-103) binds to both cdk4 and cdk6 and inhibits cdk4-cyclin D1 kinase activity in vitro (IC₅₀: 1.5 μM). [Ala92]-p16 (84-103) blocks cell cycle progression through the G1 phase .

HY-144707

AK-778-XXMU	Apoptosis VEGFR MMP PTEN	Cancer
AK-778-XXMU is a potent DNA binding inhibitor 2 (ID2) antagonist with a K_D of 129 nM. AK-778-XXMU can inhibit cell migration and invasion of glioma cell lines, induce apoptosis, and exhibits significant cancer-suppressing potency. AK-778-XXMU inhibits the ID2-KDR signaling axis, thereby down-regulating the downstream angiogenic factors (VEGFA) and invasion-related proteins (MMP2/9), and up-regulating the tumor suppressor factor (PTEN). AK-778-XXMU can be used for the study of glioma .

HY-P10424

OPBP-1	PD-1/PD-L1	Cancer
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research .

HY-B0660R

Eicosapentaenoic Acid (Standard) EPA (Standard); Timnodonic acid (Standard)	Reference Standards Endogenous Metabolite Histone Demethylase	Neurological Disease Cancer
Eicosapentaenoic Acid (Standard) is the analytical standard of Eicosapentaenoic Acid. This product is intended for research and analytical applications. Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .

HY-150229

306-N16B	Liposome	Cancer
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .

HY-B0660S1

Eicosapentaenoic acid 1,2,3,4,5-13C5 EPA 1,2,3,4,5-13C, FA 20:5-¹³C₅	Isotope-Labeled Compounds Endogenous Metabolite Histone Demethylase	Neurological Disease Cancer
Eicosapentaenoic acid 1,2,3,4,5- ¹³C₅ (EPA 1,2,3,4,5- ¹³C, FA 20:5- ¹³C₅) is ¹³C labeled Eicosapentaenoic Acid. Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .

Cat. No.	Product Name

HY-L128

E3 Ligase Ligand Library	94 compounds
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2). MCE carefully prepared a unique collection of 94 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

E3 Ligase Ligand Library

94 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation.

Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2).

MCE carefully prepared a unique collection of 94 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

HY-L015

PI3K/Akt/mTOR Compound Library	885 compounds
The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials. MCE owns a unique collection of 885 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

PI3K/Akt/mTOR Compound Library

885 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 885 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

HY-L064

Glutamine Metabolism Compound Library	1,397 compounds
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH. Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment. MCE owns a unique collection of 1,397 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Glutamine Metabolism Compound Library

1,397 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 1,397 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

HY-L045

Oxygen Sensing Compound Library	3,451 compounds
Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression. Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival. HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O₂ concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation. MCE offers a unique collection of 3,451 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

Oxygen Sensing Compound Library

3,451 compounds

Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression.

Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival.

HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O₂ concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation.

MCE offers a unique collection of 3,451 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

Cat. No.	Product Name	Type

HY-150229

306-N16B	Drug Delivery
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .

306-N16B

Drug Delivery

306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .

Cat. No.	Product Name	Target	Research Area

HY-P10424

OPBP-1	PD-1/PD-L1	Cancer
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research .

HY-P10295

p53 (232-240)	MDM-2/p53	Cancer
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .

HY-P10434

BRC4wt BRC4 repeat motif	Peptides	Cancer
BRC4wt (BRC4 repeat motif) is part of the BRACA2 tumor suppressor protein, which exhibits inhibitory activity against interaction of the BRACA2 protein with RAD51, and is involved in the repair of DNA damage .

HY-P10553

ARF(26–44), cell-permeable	Apoptosis	Cancer
ARF(26–44), cell-permeable is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. As a functional inhibitor of FoxM1, ARF(26–44) cell-permeable shows significant anti-tumor activity in the treatment of mouse hepatocellular carcinoma (HCC), significantly increasing tumor cell apoptosis and reducing tumor cell proliferation and angiogenesis. ARF(26–44), cell-permeable can be used in research on tumor therapy .

HY-P1109

[Ala92]-p16 (84-103)	CDK	Cancer
[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a (p16) tumor suppressor protein. [Ala92]-p16 (84-103) binds to both cdk4 and cdk6 and inhibits cdk4-cyclin D1 kinase activity in vitro (IC₅₀: 1.5 μM). [Ala92]-p16 (84-103) blocks cell cycle progression through the G1 phase .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0660

Eicosapentaenoic Acid 20+ Cited Publications EPA; Timnodonic acid	Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite Histone Demethylase
Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .

HY-B0660R

Eicosapentaenoic Acid (Standard) EPA (Standard); Timnodonic acid (Standard)	Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite Histone Demethylase
Eicosapentaenoic Acid (Standard) is the analytical standard of Eicosapentaenoic Acid. This product is intended for research and analytical applications. Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .

HY-W011269

Eicosapentaenoic Acid sodium EPA sodium; Timnodonic acid sodium	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Histone Demethylase
Eicosapentaenoic Acid (EPA)sodium is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid sodium exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid sodium activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid sodium can promote relaxation of vascular smooth muscle cells and vasodilation .

Species:	Human (8) Rat (1) Mouse (2)
Tag:	His (10) SUMO (1) Tag Free (1) Avi (1) Myc (1)
Source:	HEK293 (3) E. coli (8)

Cat. No.	Compare	Product Name	Species	Source

HY-P71703

	p53 Protein, Rat (His) Tp53; P53; Cellular tumor antigen p53; tumor suppressor p53	Rat	E. coli
	The p53 protein acts as a tumor suppressor, regulates the cell cycle and induces growth arrest or apoptosis.It activates genes that inhibit cell division and trigger apoptosis by controlling the expression of various proteins.p53 Protein, Rat (His) is the recombinant rat-derived p53 protein, expressed by E.coli , with N-6*His labeled tag.

HY-P76124

	VHL Protein, Human (His) von Hippel-Lindau disease tumor suppressor; protein G7; pVHL; VHL	Human	E. coli
	VHL protein is an important component of the von Hippel-Lindau ubiquitination complex and plays a key role in ubiquitination and proteasomal degradation. As a target recruitment subunit in the E3 ubiquitin ligase complex, VHL specifically recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions and regulates cellular responses to oxygen levels. VHL Protein, Human (His) is the recombinant human-derived VHL protein, expressed by E. coli , with N-6*His labeled tag.

HY-P70085

	CADM1/IGSF4A Protein, Mouse (HEK293, His) rMuCell adhesion molecule 1/CADM1, His; Cell adhesion molecule 1; Immunoglobulin superfamily member 4; IgSF4; Nectin-like protein 2; NECL-2; Synaptic cell adhesion molecule; SynCAM; tumor suppressor in lung cancer 1; TSLC-1	Mouse	HEK293
	CADM1/IGSF4A proteins coordinate Ca(2+)-independent homophilic and heterophilic cell adhesion with CADM3 and NECTIN3. Interaction with CRTAM enhances NK cell cytotoxicity and CD8+ T cell function. CADM1/IGSF4A Protein, Mouse (341a.a, HEK293, His) is the recombinant mouse-derived CADM1/IGSF4A protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P702524

	Matriptase/ST14 Catalytic Domain Protein, Mouse (His) EC 3.4.21; Epithin; HAI; Matriptase; Membrane-type serine protease 1; MTSP1; MT-SP1EC 3.4.21.109; prostamin; PRSS14; Serine protease 14; Serine protease TADG-15; SNC19; SNC19MTSP1; ST14; suppressor of tumorigenicity 14 protein; TADG15; TADG-15; TMPRSS14; tumor associated differentially expressed gene 15 protein; tumor-associated differentially-expressed gene 15 protein	Mouse	E. coli
	The Matriptase/ST14 catalytic domain protein exhibits serine-type endopeptidase activity and is critical in processes as diverse as placental branching and neural tube closure. It is an extrinsic component of the plasma membrane and is expressed in structures such as the digestive system, early concepts, genitourinary system, pituitary gland, and sense organs. Matriptase/ST14 Catalytic Domain Protein, Mouse (His) is the recombinant mouse-derived Matriptase/ST14 Catalytic Domain protein, expressed by E. coli , with N-6*His labeled tag.

HY-P702523

	Matriptase/ST14 Catalytic Domain Protein, Human (His) EC 3.4.21; Epithin; HAI; Matriptase; Membrane-type serine protease 1; MTSP1; MT-SP1EC 3.4.21.109; prostamin; PRSS14; Serine protease 14; Serine protease TADG-15; SNC19; SNC19MTSP1; ST14; suppressor of tumorigenicity 14 protein; TADG15; TADG-15; TMPRSS14; tumor associated differentially expressed gene 15 protein; tumor-associated differentially-expressed gene 15 protein	Human	E. coli
	The Matriptase/ST14 catalytic domain protein originates from epithelial cells, forms a complex with HAI-1, and is activated by sphingosine-1-phosphate. It cleaves and activates hepatocyte growth factor/scatter factor and urokinase plasminogen activator, suggesting its role as an activator of other proteases and potential growth factors. Matriptase/ST14 Catalytic Domain Protein, Human (His) is the recombinant human-derived Matriptase/ST14 Catalytic Domain protein, expressed by E. coli , with N-6*His labeled tag.

HY-P704778

	Matriptase/ST14 Catalytic Domain Protein, Human EC 3.4.21; Epithin; HAI; Matriptase; Membrane-type serine protease 1; MTSP1; MT-SP1EC 3.4.21.109; prostamin; PRSS14; Serine protease 14; Serine protease TADG-15; SNC19; SNC19MTSP1; ST14; suppressor of tumorigenicity 14 protein; TADG15; TADG-15; TMPRSS14; tumor associated differentially expressed gene 15 protein; tumor-associated differentially-expressed gene 15 protein	Human	E. coli
	The Matriptase/ST14 catalytic domain protein originates from epithelial cells, forms a complex with HAI-1, and is activated by sphingosine-1-phosphate. It cleaves and activates hepatocyte growth factor/scatter factor and urokinase plasminogen activator, suggesting its role as an activator of other proteases and potential growth factors. Matriptase/ST14 Catalytic Domain Protein, Human is the recombinant human-derived Matriptase/ST14 Catalytic Domain protein, expressed by E. coli, with tag free.

HY-P704000

	LATS1 Protein, Human (His, Myc) Large tumor suppressor homolog 1; WARTS protein kinase (h-warts); WARTS	Human	E. coli
	LATS1 Protein, Human (His, Myc) is the recombinant human-derived LATS1 protein, expressed by E. coli, with C-Myc & N-10*His tag.

HY-P705518

	Cellular tumor antigen P53/TP53 Protein, Human (His) Cellular tumor antigen p53; p53; TP53; Antigen NY-CO-13; Phosphoprotein p53; tumor suppressor p53	Human	E. coli

HY-P704124

	LYPD1 Protein, Human (HEK293, His) LYPD1,Ly6/PLAUR domain-containing protein 1,FLJ41033,LY6/PLAUR domain containing 1,LYPDC1,PHTS,Putative HeLa tumor suppressor	Human	HEK293
	LYPD1 Protein, Human (HEK293, His) is the recombinant human-derived LYPD1 protein, expressed by HEK293, with C-His tag.

HY-P705162

	LYPD1 Protein, Human (Biotinylated, HEK293, His-Avi) LYPD1,Ly6/PLAUR domain-containing protein 1,FLJ41033,LY6/PLAUR domain containing 1,LYPDC1,PHTS,Putative HeLa tumor suppressor	Human	HEK293

HY-P72178

	EEF1A1 Protein, Human (His-SUMO) CCS 3; CCS3; Cervical cancer suppressor 3; chunp6927; CTCL tumor antigen; EE1A1; EEF 1; EEF1A; eEF1A-1; EEF1A1; EF-1-alpha-1; EF-Tu; EF1A; EF1a like protein; EF1A1_HUMAN; Elongation factor 1-alpha 1; Elongation factor Tu; GRAF 1EF; HNGC:16303; ik:tdsubc_2a3; ik:tdsubc_2b3; LENG7; member 7; PTI1; tdsubc_2a3; wu:fa91c07; wu:fa94b03; wu:fi13b09; xx:tdsubc_2a3; xx:tdsubc_2b3	Human	E. coli
	EEF1A1 is a translation elongation factor that catalyzes GTP-dependent binding of aminoacyl-tRNA (aa-tRNA) to the ribosomal A site during protein synthesis. This involves mRNA codon-aa-tRNA anticodon base pairing, leading to GTP hydrolysis and aa-tRNA release in EEF1A1. EEF1A1 Protein, Human (His-SUMO) is the recombinant human-derived EEF1A1 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-16271S

Kevetrin-13C2,15N3 hydrochloride
Kevetrin (hydrochloride)- ¹³C₂, ¹⁵N₃ is the ¹³C-labeled and ¹⁵N-labeled Kevetrin (hydrochloride). Kevetrin hydrochloride is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity.

HY-B0660S1

Eicosapentaenoic acid 1,2,3,4,5-13C5

Eicosapentaenoic acid 1,2,3,4,5- ¹³C₅ (EPA 1,2,3,4,5- ¹³C, FA 20:5- ¹³C₅) is ¹³C labeled Eicosapentaenoic Acid. Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P86304

	LATS1 Antibody (YA5996) Serine/threonine-protein kinase LATS1; Large tumor suppressor homolog 1; WARTS protein kinase; h-warts;	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	LATS1 Antibody (YA5996) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LATS1.

HY-P81210

	phospho-LATS1+LATS2 (Thr1079 +Thr1041) Antibody LATS1 +LATS2 (phospho T1079 + T1041); Serine/threonine protein kinase LATS2; KPM; Large tumor supressor, homolog 1; LATS, large tumor suppressor, homolog 1 (Drosophila); LATS, large tumor suppressor, homolog 2 (Drosophila); LATS1 +LATS2 (phospho T1079 + T1041); p-LATS1 +LATS2(Thr1079 +Thr1041); RGD1564085; Serine/threonine protein kinase LATS1; WARTS; WARTS protein kinase; wts; 4932411G09Rik; AV277261; AW208599; AW228608; FLJ13161; LATS1_HUMAN.	WB, ELISA, IHC-P, IHC-F, ICC/IF	Human, Mouse
	phospho-LATS1+LATS2 (Thr1079 +Thr1041) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to phospho-LATS1+LATS2 (Thr1079 +Thr1041).

HY-P87326

	Hamartin Antibody (YA7009) Hamartin antibody; kiaa0243 antibody; LAM antibody; TSC antibody; Tsc1 antibody; Tsc1 gene antibody; TSC1_HUMAN antibody; Tuberous sclerosis 1 antibody; Tuberous sclerosis 1 protein antibody; tumor suppressor antibody	WB, IP	Human, Mouse, Rat, Monkey
	Hamartin Antibody (YA7009) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Hamartin.

HY-P86169

	p53 Antibody (YA5861) Antigen NY-CO-13; BCC7; Cellular tumor antigen p53; FLJ92943; LFS1; Mutant tumor protein 53; p53; p53 tumor suppressor; P53_HUMAN; Phosphoprotein p53; Tp53; Transformation related protein 53; TRP53; tumor antigen p55; tumor protein 53; tumor protein p53; tumor suppressor p53;	WB, IHC-P, ICC/IF, IP, ELISA	Human
	p53 Antibody (YA5861) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p53.

HY-P86435

	53BP1 Antibody (YA6127) TP53BP1; tumor suppressor p53-binding protein 1; 53BP1; p53-binding protein 1; p53BP1	WB, ICC/IF, IP, ELISA	Human
	53BP1 Antibody (YA6127) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to 53BP1.

HY-P85433

	Hsc70 Interacting Protein Antibody (YA5125) ST13; AAG2; FAM10A1; HIP; SNC6; Hsc70-interacting protein; Hip; Aging-associated protein 2; Progesterone receptor-associated p48 protein; protein FAM10A1; Putative tumor suppressor ST13; Renal carcinoma antigen NY-REN-33; Suppression of tum	WB, IHC-P, ICC/IF	Human, Bovine, Dog, Pig
	Hsc70 Interacting Protein Antibody (YA5125) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Hsc70 Interacting Protein.

HY-P86277

	TP53BP2 Antibod (YA5969) TP53BP2; ASPP2; BBP; Apoptosis-stimulating of p53 protein 2 ; Bcl2-binding protein; Bbp; Renal carcinoma antigen NY-REN-51; tumor suppressor p53-binding protein 2; 53BP2; p53-binding protein 2; p53BP2;	WB, IHC-P, ICC/IF, ICC	Human
	TP53BP2 Antibody (YA5969) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TP53BP2.

HY-P86919

	PAX6 Antibody(YA6612) AN 2 antibody; AN antibody; AN2 antibody; Aniridia type II protein antibody; D11S812E antibody; FVH1 antibody; KIAA0552 antibody; Leucine zipper putative tumor suppressor 3 antibody; LZTS3 antibody; MGC17209 antibody; AN 2 antibody; AN antibody; AN2 antibody; Aniridia type II protein antibody; D11S812E antibody; FVH1 antibody; KIAA0552 antibody; Leucine zipper putative tumor suppressor 3 antibody; LZTS3 antibody; MGC17209 antibody; MGDA antibody; Oculorhombin antibody; Paired box 6 antibody; Paired box gene 6 (aniridia keratitis) antibody; Paired Box Gene 6 antibody; Paired box homeotic gene 6 antibody; Paired box protein Pax-6 antibody; Paired box protein Pax6 antibody; PAX 6 antibody; PAX6 antibody; PAX6_HUMAN antibody; ProSAP-interacting protein 1 antibody; PROSAPIP1 antibody; Sey antibody; WAGR antibody;	mIHC	Mouse
	PAX6 Antibody(YA6612) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PAX6.

HY-P86845

	DCC Antibody (YA6538) Colorectal cancer related chromosome sequence 18 antibody; Colorectal cancer suppressor antibody; CRC 18 antibody; CRC18 antibody; CRCR 1 antibody; CRCR1 antibody; DCC antibody; DCC_HUMAN antibody; Deleted in colorectal cancer protein antibody; Deleted in colorectal carcinoma antibody; Colorectal cancer related chromosome sequence 18 antibody; Colorectal cancer suppressor antibody; CRC 18 antibody; CRC18 antibody; CRCR 1 antibody; CRCR1 antibody; DCC antibody; DCC_HUMAN antibody; Deleted in colorectal cancer protein antibody; Deleted in colorectal carcinoma antibody; Immunoglobulin superfamily DCC subclass member 1 antibody; Netrin receptor DCC antibody; tumor suppressor protein DCC antibody;	WB, IHC-F	Human, Mouse, Rat
	DCC Antibody (YA6538) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DCC.

HY-P85957

	SMARCB1 Antibody (YA5649) BAF47; BRG1-associated factor 47; hSNF5; INI1; Integrase interactor 1 protein; Malignant rhabdoid tumor suppressor; RDT; RTPS1; Sfh1p; SMARCB1; SNF5 homolog; SNF5_HUMAN; SNF5L1; Snr1; Sucrose nonfermenting yeast homolog like 1; SWI/SNF complex component SNF5; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1; SWI10; Transcription factor TYE4; Transcription regulatory protein SNF5; TYE4	IHC-P, WB, ICC/IF, ELISA	Human, Mouse,
	SMARCB1 Antibody (YA5649) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to SMARCB1.

HY-P80095

	Ctip2 Antibody (YA488) ATL1 alpha antibody; ATL1 antibody; ATL1 beta antibody; ATL1 gamma antibody; ATL1-delta antibody; B-cell CLL/lymphoma 11B antibody; B-cell lymphoma/leukemia 11B antibody; BC11B_HUMAN antibody; BCL-11B antibody; Bcl11b antibody; BCL11B/TRDC fusion antibody; COUP TF interacting protein 2 antibody; Ctip 2 antibody; CTIP-2 antibody; CTIP2 antibody; hRIT1 alpha antibody; hRit1 antibody; Radiation induced tumor suppressor gene 1 antibody; Rit 1 antibody; zinc finger protein hRit1 alpha antibody; ZNF856B antibody	WB, ICC/IF, IHC-P, FC	Human, Mouse
	Ctip2 Antibody (YA488) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Ctip2.

HY-P86790

	BRCA2 Antibody (YA6483) BRCA 2 antibody; BRCA1/BRCA2 containing complex subunit 2 antibody; Brca2 antibody; BRCA2, DNA repair associated antibody; BRCA2_HUMAN antibody; BRCC 2 antibody; BRCC2 antibody; Breast and ovarian cancer susceptibility gene early onset antibody; breast and ovarian cancer susceptibility protein 2 antibody; Breast cancer 2 early onset antibody; BRCA 2 antibody; BRCA1/BRCA2 containing complex subunit 2 antibody; Brca2 antibody; BRCA2, DNA repair associated antibody; BRCA2_HUMAN antibody; BRCC 2 antibody; BRCC2 antibody; Breast and ovarian cancer susceptibility gene early onset antibody; breast and ovarian cancer susceptibility protein 2 antibody; Breast cancer 2 early onset antibody; Breast Cancer 2 tumor suppressor antibody; Breast cancer susceptibility protein BRCA2 antibody; Breast cancer type 2 susceptibility protein antibody; BROVCA2 antibody; FACD antibody; FAD 1 antibody; FAD antibody; FAD1 antibody; FANCB antibody; FANCD 1 antibody; FANCD antibody; FANCD1 antibody; FANCD1 gene antibody; Fanconi anemia complementation group D1 antibody; Fanconi anemia group D1 protein antibody; GLM3 antibody; mutant BRCA2 antibody; OTTHUMP00000018803 antibody; OTTHUMP00000042401 antibody; PNCA2 antibody; XRCC11 antibody;	WB, FC	Human
	BRCA2 Antibody (YA6483) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRCA2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-150229

306-N16B		Cationic Lipids
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .

HY-174511

Human TP53 mRNA		mRNA
Human TP53 mRNA encodes the human tumor protein p53 (TP53) protein, a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. TP53 responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism.

HY-174777

Human BAK1 mRNA		mRNA
Human BAK1 mRNA encodes the human BCL2 antagonist/killer 1 (BAK1) protein, a member of the BCL2 protein family. BAK1 localizes to mitochondria, and functions to induce apoptosis. It also interacts with the tumor suppressor P53 after exposure to cell stress.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

tumor suppressor protein

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products